Intravenous administration of a tissue plasminogen activator beyond 3 hours of the onset of acute ischemic stroke - MRI-based decision making

Brain and Nerve

Volumn 60, Issue 10, 2008, Pages 1173-1180

  Kakuda, Wataru ^a   Abo, Masahiro ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute ischemic stroke; PWI DWI mismatch; Stroke MRI; Thrombolysis; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; DESMOTEPLASE; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG EFFECT; DRUG USE; ECHO PLANAR IMAGING; HUMAN; MEDICAL DECISION MAKING; NUCLEAR MAGNETIC RESONANCE IMAGING; REPERFUSION; REVIEW; STROKE; TREATMENT RESPONSE;

HUMANS; INFUSIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; PLASMINOGEN ACTIVATORS; STROKE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 54149117806     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. The NINDS rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333: 1581-1587, 1995
2. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffee E, et al: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS). JAMA 274: 1017-1025, 1995
3. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, et al: Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS-2). Lancet 352: 1245-1251, 1998
4. Clark WM, Wissman S, Albers GW, Jhmandas JH, Madden KP, et al: Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset: The ATLANTIS Study: A randomized controlled trial. JAMA 282: 2019-2026, 1999
5. Qureshi AI, Kirmani JF, Sayed MA, Safdar A, Ahmed S, et al: Time to hospital arrival, use of thrombolysis, and in-hospital outcomes in ischemic stroke. Neurology 64: 2115-2120, 2005
6. Albers GW: Expanding the window for thrombolytic therapy in acute stroke: The potential role of acute MRI for patient selection. Stroke 30: 2230-2237, 1999
7. Kidwell CS, Saver JL, Starkman S, Duckwiler G, Jahan R, et al: Late secondary ischemic injury in patients receiving intraarterial thrombolysis. Ann Neurol 52: 698-703, 2002
8. Baird AE, Benfield A, Schlaug G, Siewert B, Lovblad KO, et al: Enlargement of human cerebral ischemic lesion volumes measured by diffusion-weighted magnetic resonance imaging. Ann Neurol 41: 581-589, 1997
9. Kidwell CS, Alger JR, Saver JL: Beyond mismatch: Evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging. Stroke 34: 2729-2735, 2003
10. Darby DG, Barber PA, Gerraty RP, Desmond PM, Yang Q, et al: Pathophysiological topography of acute ischemia by combined diffusion-weighted and perfusion MRI. Stroke 31: 2043-2052, 1999
11. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, et al: The desmoteplase in acute ischemic stroke trial (DIAS): A phase 2 MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36: 66-73, 2005
12. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, et al: Dose escalation of desmoteplase for acute ischemic stroke (DEDAS): Evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 37: 1227-1231, 2006
13. Hacke W, Furlan A, for the DIAS-2 investigators: Results from the phase 3 study of desmoteplase in acute ischemic stroke trial-2: Abstracts from 16th European Stroke Conference. Cerebrovascular Diseases 23 (suppl2): 54, 2007
14. Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, et al: Magnetic resonance imaging profiles predict clinical response to early reperfusion: The Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) Study. Ann Neurol 60: 508-517, 2006
15. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, et al: Effects of alteplase beyond 3h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomized trial. Lancet Neurol 7: 299-309, 2008
16. Kakuda W, Lansberg MG, Thijs VN, Kemp SM, Bammer R, et al: Optimal definition for PWI/DWI mismatch in acute ischemic stroke patients. J Cereb Blood Flow Metab 28: 887-891, 2008
17. Kane I, Carpenter T, Chappell F, Rivers C, Armitage P, et al: Comparison of 10 different magnetic resonance perfusion imaging processing methods in acute ischemic stroke: Effect on lesion size, proportion of patients with diffusion/perfusion mismatch, clinical scores, and radiologic outcomes. Stroke 38: 3158-3164, 2007
18. Davalos A, Blanco M, Pedraza S, Leira R, Castellanos M, et al: The clinical-DWI mismatch: A new diagnostic approach to the brain tissue at risk of infarction. Neurology 62: 2187-2192, 2004
19. Prosser J, Butcher K, Allport L, Parsons M, MacGregor L, et al: Clinical-diffusion mismatch predicts the putative penumbra with high specificity. Stroke 36: 1700-1704, 2005
20. Lansberg MG, Thijs VN, Bammer R, Kakuda W, Wechsler LR, et al: Can magnetic resonance angiography replace perfusion-weighted imaging in the magnetic resonance imaging mismatch model?: Abstracts from the 2007 International Stroke Conference. Stroke 38: 494, 2007
21. Hjort N, Butcher K, Davis SM, Kidwell SC, Koroshtz WJ, et al: Magnetic resonance imaging criteria for thrombolysis in acute cerebral infarct. Stroke 36: 388-397, 2005
22. Schellinger PD, Thomalla G, Fiehler J, Kohrmann M, Molina CA, et al: MRI-based and CT-based thrombolytic therapy in acute stroke within and beyond established time windows: An analysis of 1210 patients. Stroke 38: 2640-2645, 2007